Flow Neuroscience has acquired the assets of brain stimulation technology developer Halo Neuroscience to advance its research into depression and other mental health disorder treatments.
The financial details of the deal have not been disclosed.
Using Halo’s research in neuromodulation field, Flow Neuroscience plans to enhance its current medically certified tDCS headset for depression. It will also partner with clinicians to address other critical medical needs such as rehabilitation and motor impairment.
A form of neuromodulation, tDCS uses constant, low direct current delivered via electrodes on the head.
The headset helps to stimulate neurons in a particular area using tDCS.
It is used along with Flow’s depression app, directing users through various personalised exercises informed by behavioural therapy.
The user-friendly headset and app of Flow are effective in reducing the symptoms of depression in an at-home setting, maintaining the patient’s comfort.
Flow Neuroscience CEO and co-founder and clinical psychologist Daniel Mansson said: “Our aim is to dramatically improve the lives of people who struggle with their mental health.
“Halo’s technology and academic research complement that of Flows’ in an almost magical way and will help us to take a very important next step on this journey together with our community of users.”
According to the National Health Service (NHS) UK, brain stimulation is effective in treating unipolar depression and is also proven to have a similar effect to antidepressants without the side-effects.
Halo CEO and co-founder Brett Wingeier: “Flow is the best possible successor and a great home for everything we built at Halo with the help of our team, our customers, and our collaborators.
In July 2019, Flow announced that it raised $1.5m towards its transcranial direct current stimulation (tDCS) device for the treatment of depression.